Club cell protein 16 and disease progression in chronic obstructive pulmonary disease

Hye Yun Park, Andrew Churg, Joanne L. Wright, Yuexin Li, Sheena Tam, S. F.Paul Man, Donald Tashkin, Robert A. Wise, John E Connett, Don D. Sin

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Rationale: Club (Clara) cell protein 16 (CC-16) is a protein that is synthesized predominantly in the lungs and is detectable in serum. Its expression decreases with lung injury and smoking, and is thus a marker of bronchial cell dysfunction. Objectives: To evaluate the possibility of using serum CC-16 as a biomarker for disease progression in chronic obstructive pulmonary disease (COPD). Methods:We measured serum CC-16 levels from 4,724 subjects with mild-to-moderate airflow limitation in the Lung Health Study. Using a linear regression model, we determined the relationship of serum CC-16 concentrations to decline in lung function over 9 years. In addition, to determine whether CC-16 plays a major role in the pathogenesis of mild COPD, we exposed CC-16-deficient (2/2) mice to 6 months of cigarette smoke. Measurements and Main Results: Reduced serum concentrations of CC-16 were associated with accelerated decline in FEV1 over 9 years (P , 0.0001), and this association persisted after adjustments for age, sex, race, smoking status, airway reactivity, body mass index, and baseline FEV1 (P = 0.0002). However, CC-162/2 mice did not demonstrateanenhancedrisk ofemphysemaor small airway remodeling in response to cigarette smoke. Conclusions: Serum CC-16 is associated with disease progression, and may assist in the identification of "rapid progressors." However, the absence of CC-16 does not appear to modify the risk of cigaretterelated COPD in mice.

Original languageEnglish (US)
Pages (from-to)1413-1419
Number of pages7
JournalAmerican journal of respiratory and critical care medicine
Volume188
Issue number12
DOIs
StatePublished - Dec 15 2013

Fingerprint

Chronic Obstructive Pulmonary Disease
Disease Progression
Serum
Proteins
Smoke
Tobacco Products
Lung
Linear Models
Smoking
Airway Remodeling
Lung Injury
Body Mass Index
Biomarkers
Health

Keywords

  • Biomarker
  • Chronic obstructive pulmonary disease
  • Disease progression
  • Smoking

Cite this

Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. / Park, Hye Yun; Churg, Andrew; Wright, Joanne L.; Li, Yuexin; Tam, Sheena; Man, S. F.Paul; Tashkin, Donald; Wise, Robert A.; Connett, John E; Sin, Don D.

In: American journal of respiratory and critical care medicine, Vol. 188, No. 12, 15.12.2013, p. 1413-1419.

Research output: Contribution to journalArticle

Park, HY, Churg, A, Wright, JL, Li, Y, Tam, S, Man, SFP, Tashkin, D, Wise, RA, Connett, JE & Sin, DD 2013, 'Club cell protein 16 and disease progression in chronic obstructive pulmonary disease', American journal of respiratory and critical care medicine, vol. 188, no. 12, pp. 1413-1419. https://doi.org/10.1164/rccm.201305-0892OC
Park, Hye Yun ; Churg, Andrew ; Wright, Joanne L. ; Li, Yuexin ; Tam, Sheena ; Man, S. F.Paul ; Tashkin, Donald ; Wise, Robert A. ; Connett, John E ; Sin, Don D. / Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. In: American journal of respiratory and critical care medicine. 2013 ; Vol. 188, No. 12. pp. 1413-1419.
@article{6ea3b0a510e44b298c5f1698aea7acb5,
title = "Club cell protein 16 and disease progression in chronic obstructive pulmonary disease",
abstract = "Rationale: Club (Clara) cell protein 16 (CC-16) is a protein that is synthesized predominantly in the lungs and is detectable in serum. Its expression decreases with lung injury and smoking, and is thus a marker of bronchial cell dysfunction. Objectives: To evaluate the possibility of using serum CC-16 as a biomarker for disease progression in chronic obstructive pulmonary disease (COPD). Methods:We measured serum CC-16 levels from 4,724 subjects with mild-to-moderate airflow limitation in the Lung Health Study. Using a linear regression model, we determined the relationship of serum CC-16 concentrations to decline in lung function over 9 years. In addition, to determine whether CC-16 plays a major role in the pathogenesis of mild COPD, we exposed CC-16-deficient (2/2) mice to 6 months of cigarette smoke. Measurements and Main Results: Reduced serum concentrations of CC-16 were associated with accelerated decline in FEV1 over 9 years (P , 0.0001), and this association persisted after adjustments for age, sex, race, smoking status, airway reactivity, body mass index, and baseline FEV1 (P = 0.0002). However, CC-162/2 mice did not demonstrateanenhancedrisk ofemphysemaor small airway remodeling in response to cigarette smoke. Conclusions: Serum CC-16 is associated with disease progression, and may assist in the identification of {"}rapid progressors.{"} However, the absence of CC-16 does not appear to modify the risk of cigaretterelated COPD in mice.",
keywords = "Biomarker, Chronic obstructive pulmonary disease, Disease progression, Smoking",
author = "Park, {Hye Yun} and Andrew Churg and Wright, {Joanne L.} and Yuexin Li and Sheena Tam and Man, {S. F.Paul} and Donald Tashkin and Wise, {Robert A.} and Connett, {John E} and Sin, {Don D.}",
year = "2013",
month = "12",
day = "15",
doi = "10.1164/rccm.201305-0892OC",
language = "English (US)",
volume = "188",
pages = "1413--1419",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "12",

}

TY - JOUR

T1 - Club cell protein 16 and disease progression in chronic obstructive pulmonary disease

AU - Park, Hye Yun

AU - Churg, Andrew

AU - Wright, Joanne L.

AU - Li, Yuexin

AU - Tam, Sheena

AU - Man, S. F.Paul

AU - Tashkin, Donald

AU - Wise, Robert A.

AU - Connett, John E

AU - Sin, Don D.

PY - 2013/12/15

Y1 - 2013/12/15

N2 - Rationale: Club (Clara) cell protein 16 (CC-16) is a protein that is synthesized predominantly in the lungs and is detectable in serum. Its expression decreases with lung injury and smoking, and is thus a marker of bronchial cell dysfunction. Objectives: To evaluate the possibility of using serum CC-16 as a biomarker for disease progression in chronic obstructive pulmonary disease (COPD). Methods:We measured serum CC-16 levels from 4,724 subjects with mild-to-moderate airflow limitation in the Lung Health Study. Using a linear regression model, we determined the relationship of serum CC-16 concentrations to decline in lung function over 9 years. In addition, to determine whether CC-16 plays a major role in the pathogenesis of mild COPD, we exposed CC-16-deficient (2/2) mice to 6 months of cigarette smoke. Measurements and Main Results: Reduced serum concentrations of CC-16 were associated with accelerated decline in FEV1 over 9 years (P , 0.0001), and this association persisted after adjustments for age, sex, race, smoking status, airway reactivity, body mass index, and baseline FEV1 (P = 0.0002). However, CC-162/2 mice did not demonstrateanenhancedrisk ofemphysemaor small airway remodeling in response to cigarette smoke. Conclusions: Serum CC-16 is associated with disease progression, and may assist in the identification of "rapid progressors." However, the absence of CC-16 does not appear to modify the risk of cigaretterelated COPD in mice.

AB - Rationale: Club (Clara) cell protein 16 (CC-16) is a protein that is synthesized predominantly in the lungs and is detectable in serum. Its expression decreases with lung injury and smoking, and is thus a marker of bronchial cell dysfunction. Objectives: To evaluate the possibility of using serum CC-16 as a biomarker for disease progression in chronic obstructive pulmonary disease (COPD). Methods:We measured serum CC-16 levels from 4,724 subjects with mild-to-moderate airflow limitation in the Lung Health Study. Using a linear regression model, we determined the relationship of serum CC-16 concentrations to decline in lung function over 9 years. In addition, to determine whether CC-16 plays a major role in the pathogenesis of mild COPD, we exposed CC-16-deficient (2/2) mice to 6 months of cigarette smoke. Measurements and Main Results: Reduced serum concentrations of CC-16 were associated with accelerated decline in FEV1 over 9 years (P , 0.0001), and this association persisted after adjustments for age, sex, race, smoking status, airway reactivity, body mass index, and baseline FEV1 (P = 0.0002). However, CC-162/2 mice did not demonstrateanenhancedrisk ofemphysemaor small airway remodeling in response to cigarette smoke. Conclusions: Serum CC-16 is associated with disease progression, and may assist in the identification of "rapid progressors." However, the absence of CC-16 does not appear to modify the risk of cigaretterelated COPD in mice.

KW - Biomarker

KW - Chronic obstructive pulmonary disease

KW - Disease progression

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=84890541399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890541399&partnerID=8YFLogxK

U2 - 10.1164/rccm.201305-0892OC

DO - 10.1164/rccm.201305-0892OC

M3 - Article

VL - 188

SP - 1413

EP - 1419

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 12

ER -